Semaglutide 5mg

Name: Semaglutide 5mg
SKU: PL-5MG-PL02
Price: 185.00 USD
Availability: InStock

Brands PeptideLion

$185.00

out of stock

Sku:

PL-5MG-PL02

Brands: PeptideLion

Description

Overview

What is Semaglutide?

Semaglutide belongs to a class of medications known as glucagon-like peptide-1 receptor agonists, or GLP-1 RAs. It mimics the GLP-1 hormone, released in the gut in response to eating. One role of GLP-1 is to prompt the body to produce more insulin, which reduces blood sugar (glucose). For that reason, healthcare providers have used semaglutide for more than 15 years to treat Type 2 diabetes.

Higher amounts of GLP-1 also interact with parts of the brain that suppress appetite and signal feelings of fullness. When combined with diet and exercise, it can lead to significant weight loss and reduce the risk of cancer, diabetes, and heart disease in people who are obese or overweight.

Who Is a Good Candidate for Semaglutide?

“A good candidate for Ozempic is someone who is comfortable providing a weekly self-injection, has a medical history of type 2 diabetes and an elevated body mass index (BMI) of at least 27,” says Dr. Saunders. Similarly, a good candidate for Rybelsus has a medical history of type 2 diabetes and a BMI of 27 or more, she says. A good candidate for Wegovy must also be comfortable with a weekly self-injection and have a BMI of 30 (with or without weight-related health complications) or a BMI of at least 27 with at least one weight-related health complication (like high cholesterol or hypertension), explains Dr. Saunders.

Scientific Information

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is available as monotherapy in both subcutaneous and oral dosage forms (the first approved oral GLP-1 receptor agonist). The FDA has approved it as a second-line treatment for better glycemic control in type 2 diabetes, and it is currently under investigation for anti-obesity purposes. Studies have shown that semaglutide is safe for adults and elderly patients with renal or hepatic disorders, without requiring dose modification. Cardiovascular (CV) outcome trials demonstrated that it can reduce various CV risk factors in patients with established CV disorders. Although semaglutide is well-tolerated and has no risk of hypoglycemia when used as monotherapy, it can cause gastrointestinal adverse effects.

A large population affected with COVID-19 infection were diabetic; therefore, the use of semaglutide in diabetes as well as CV patients would be very supportive in maintaining the health care system during this pandemic situation. Hence, this peptidic drug can be truly considered a quintessential GLP-1 agonist for the management of type 2 diabetes.

Research Highlights

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the activity of GLP-1, a hormone released in the intestine after eating. GLP-1 triggers insulin production, which lowers blood sugar levels, and interacts with parts of the brain to reduce hunger and promote feelings of satiety. The FDA has approved different forms of semaglutide for treating type 2 diabetes and obesity when combined with diet and exercise.

If you are obese, overweight, or struggling to lose weight, a simple peptide called semaglutide may be a game-changer. Though the name sounds complex, this GLP-1 RA mimics the GLP-1 hormone released in the digestive system. As a result, it suppresses appetite, which is why combining it with a healthier diet and exercise can lead to weight loss. It also became the first drug in seven years to receive FDA approval for treating obesity, which is an impressive achievement. Additionally, semaglutide proves more effective than other GLP-1 RAs in improving glycemia and other cardio-metabolic risk factors in individuals with T2DM.